Efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis: A randomized, double-blind, placebo-controlled trial

Kun Huang(University of British Columbia), Min Zheng(UNSW Sydney), Yuling Shi(Tongji University), Jinhua Xu(Yuxian People's Hospital), Zhenying Zhang(Henan Provincial Center for Disease Control and Prevention), Yan Lü(Medical College of Wisconsin), Bin Yang(Southern Medical University), Xiaohua Tao(Zhejiang Provincial People's Hospital), Juan Tao(Union Hospital), Rong Xiao(Tongji University), Wei Yan(Sichuan University), Qianjin Lu(Central South University), Shuzheng Lyu(Johnson & Johnson (United Kingdom)), Furen Zhang(Shandong Provincial Institute of Dermatology and Venereology), Songmei Geng(Second Affiliated Hospital of Xi'an Jiaotong University), Yuhan Huang(University of Illinois Urbana-Champaign), Liangdan Sun(North China University of Science and Technology), Lu Wang(Chinese General Hospital College of Nursing and Liberal Arts), Ming Chen(First Affiliated Hospital Zhejiang University), Rui Wang(Sun Yat-sen University), Chunlei Zhang(Peking University), Juan Su(Ministry of Education), Hao Cheng(Sir Run Run Shaw Hospital), Zhiming Li(Boai Hospital of Zhongshan), Jie Zheng(Tangshan People's Hospital), Zhiqiang Song(Southwest General Health Center), Litao Zhang(Tianjin University of Traditional Chinese Medicine), Tong Zhang(South China Agricultural University), Huiping Wang(Chinese National Human Genome Center), Weilong Zhao(Johnson & Johnson (United Kingdom)), Shoumin Zhang(Zhengzhou University), Xiumin Yang(Beijing Tongren Hospital), Zhongqi Dong(Johnson & Johnson (United Kingdom)), Chao Ji(Zhongshan Hospital of Xiamen University)
Chinese Medical Journal
September 8, 2025
Cited by 0


Related Papers